People in brief | Valbiotis, Akorn, Venture Life

People in brief | Valbiotis, Akorn, Venture Life
Josep Infesta has worked for several of the world's leading consumer healthcare companies

30 January 2019 - Deborah Wilkes

Valbiotis, Akorn and Venture Life have all recently announced people changes.

Josep Infesta joins Valbiotis

Valbiotis – a French research and development company specialising in metabolic diseases – has appointed Josep Infesta as head of global business development.

Infesta has 25 years of experience in the consumer healthcare industry, working for a number of leading players including Johnson & Johnson, Pfizer Consumer Healthcare, Sanofi Consumer Healthcare and Warner-Lambert Consumer Healthcare. In 2017, he founded strategy consulting company IZ3.

Commenting on his new role, Infesta said he would bring complementary skills and knowledge of the consumer healthcare markets in Europe and the US to the Valbiotis team.

Valbiotis said Infesta would focus on partnership discussions for the launch of Valedia – a plant-based product for reducing the risk of type 2 diabetes in prediabetic populations – in Europe and North America.

The company added that Phase IIA results for Valedia in prediabetes were expected in mid-2019 with the aim of launching the product in 2021.

Akorn recruits from Alvogen

Akorn has appointed Christopher Young as executive vice president, global operations. He reports to Douglas Boothe who joined the US-based generics, consumer healthcare and animal health company on 1 January 2019 as president and chief executive officer.

Young was previously executive vice president, global operations at Alvogen.

Adrian Crockett leaves Venture Life

Self-care group Venture Life has announced that chief financial officer Adrian Crockett has left the business with immediate effect to "pursue other opportunities".

The UK-based company also announced that it expects to report sales of GBP18.7 million (USD24.5 million) in 2018, representing a rise of 16% compared to 2017.

Venture Life recently acquired the Dentyl mouthwash from fellow UK company DDD for GBP4.2 million in cash (click here to read the News story).

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE

Back to Industry News

Share this page: